Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials.

Pagano G, Trundell D, Simuni T, Pavese N, Marek K, Postuma RB, Shariati N, Monnet A, Moore E, Davies EW, Svoboda H, Pross N, Bonni A, Nikolcheva T, PASADENA Investigators, Prasinezumab Study Group

Open source

DOI: 10.1038/s41531-025-01041-9
Published: 2025 Jul 1
Container: NPJ Parkinson's disease
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41531-025-01041-9,
  title = {Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials.},
  author = {Pagano G and Trundell D and Simuni T and Pavese N and Marek K and Postuma RB and Shariati N and Monnet A and Moore E and Davies EW and Svoboda H and Pross N and Bonni A and Nikolcheva T and PASADENA Investigators and Prasinezumab Study Group},
  year = {2025},
  journal = {NPJ Parkinson's disease},
  doi = {10.1038/s41531-025-01041-9},
  url = {https://doi.org/10.1038/s41531-025-01041-9}
}

RIS

TY  - JOUR
TI  - Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials.
AU  - Pagano G
AU  - Trundell D
AU  - Simuni T
AU  - Pavese N
AU  - Marek K
AU  - Postuma RB
AU  - Shariati N
AU  - Monnet A
AU  - Moore E
AU  - Davies EW
AU  - Svoboda H
AU  - Pross N
AU  - Bonni A
AU  - Nikolcheva T
AU  - PASADENA Investigators
AU  - Prasinezumab Study Group
PY  - 2025
JO  - NPJ Parkinson's disease
DO  - 10.1038/s41531-025-01041-9
UR  - https://doi.org/10.1038/s41531-025-01041-9
ER  -

APA

G, P., D, T., T, S., N, P., K, M., RB, P., N, S., A, M., E, M., EW, D., H, S., N, P., A, B., T, N., Investigators, P., & Group, P. S. (2025). Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials.. NPJ Parkinson's disease. https://doi.org/10.1038/s41531-025-01041-9

Source records

pubmed · retrieved 2026-09-27T15:10:15.773Z